Improving the management of patients with atherosclerotic cardiovascular disease - The evolving role of icosapent ethyl - PACE-CME

Episodes 1-7 of 7

Integrating icosapent ethyl in cardiovascular risk reduction strategies: Practical guidance
Integrating icosapent ethyl in cardiovascular risk reduction strategies: Practical guidance
MinuteCE®
Integrating icosapent ethyl in cardiovascular risk reduction strategies: Practical guidance
1.00 program credit
- Pam R. Taub, MD, FACC, FASPC
1.00 program credit
MinuteCE®
Improving the management of patients with atherosclerotic cardiovascular disease - The evolving role of icosapent ethyl
1.00 credit 3 episodes
- Erik Stroes, MD, PhD
- P. Gabriel Steg, MD
- Pam R. Taub, MD, FACC, FASPC
1.00 credit 3 episodes
Challenges in ASCVD reduction and TG-related risk
Challenges in ASCVD reduction and TG-related risk
MinuteCE®
Challenges in ASCVD reduction and TG-related risk
1.00 program credit
- Erik Stroes, MD, PhD
1.00 program credit
Perspectives on the results of recent clinical outcomes trials with EPA prevention
Perspectives on the results of recent clinical outcomes trials with EPA prevention
MinuteCE®
Perspectives on the results of recent clinical outcomes trials with EPA prevention
1.00 program credit
- P. Gabriel Steg, MD
1.00 program credit
Integrating icosapent ethyl in cardiovascular risk reduction strategies: Practical guidance
Integrating icosapent ethyl in cardiovascular risk reduction strategies: Practical guidance
Improving the management of patients with atherosclerotic cardiovascular disease - The evolving role of icosapent ethyl
Integrating icosapent ethyl in cardiovascular risk reduction strategies: Practical guidance
- Maria Luiza Caramori, MD, PhD
Perspectives on the results of recent clinical outcomes trials with EPA
Perspectives on the results of recent clinical outcomes trials with EPA
Improving the management of patients with atherosclerotic cardiovascular disease - The evolving role of icosapent ethyl
Perspectives on the results of recent clinical outcomes trials with EPA
Challenges in ASCVD reduction and TG-related risk
Challenges in ASCVD reduction and TG-related risk
Improving the management of patients with atherosclerotic cardiovascular disease - The evolving role of icosapent ethyl
Challenges in ASCVD reduction and TG-related risk
- Erik Stroes, MD, PhD